BRANFORD, Conn. , Aug. 29, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today that Travis Whitfill , COO, will present an overview of the Company at the H.C.
BRANFORD, Conn. , Aug. 14, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the second quarter ended June 30, 2023 .
BRANFORD, Conn. , July 19, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of two members to its board of directors, Barbara Ryan and John Schroer .
BRANFORD, Conn. , July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr.
BRANFORD, Conn. , June 21, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products, today announced the closing of its
BRANFORD, Conn. , June 15, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR) (the "Company"), a biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products, today announced the pricing of its